HNSCCs overexpressing wild-type HRAS are sensitive to combined tipifarnib and alpelisib treatment. (October 2022) - Soifer, H.; Mishra, V.; Malik, S.; Smith, A.; Chan, S.; Kessler, L.; Burrows, F.; Leoni, M.; Saunders, A.; Dale, S.